Anzeige
Mehr »
Login
Samstag, 28.09.2024 Börsentäglich über 12.000 News von 691 internationalen Medien
Von 0,059 € auf 0,26 €: Die Gold-Aktie, die alle Erwartungen übertrifft
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
259 Leser
Artikel bewerten:
(1)

Cymulate Continues Exceptional Growth Trend in 2021 as Ransomware and Supply Chain Attacks Mount

Company grows 100% in revenue, and over 150% increase in personnel

Launches community platform offering a supportive environment for security professionals

NEW YORK and TEL AVIV, Israel, Jan. 19, 2022 /PRNewswire/ -- Cymulate, the Extended Security Posture Management market leader, today announced it has achieved 100% revenue growth globally, and 200% growth in North America in new bookings in 2021. The company, whose customers include Fortune 500 companies, increased personnel by 150% in North America, EMEA and APAC.

Cymulate Logo

In May 2021, Cymulate announced a Series C funding round of $45M, bringing their total funding raised to date to $71M, led by One Peak, together with existing investors Susquehanna Growth Equity (SGE), Vertex Ventures Israel, Vertex Growth and Dell Technologies Capital. Another key business milestone in 2021 was an expansion of operations into Asia with Japanese telecoms giant NTT, building on Cymulate's existing distributor agreements with NTT entities in the USA and Europe.

"2021 was the Year of Ransomware with cybercrime reaching an all time high," said Eyal Wachsman, CEO and co-founder of Cymulate. "We can expect a continuation in these attacks in 2022 with a specific focus on supply chain attacks, however we are also seeing a positive trend in that decision makers at the business level are starting to pay attention and proactively seek solutions to mitigate damages. The result has impacted Cymulate with our solid growth continuing year-over-year. We have grown our stellar team tremendously, and we look forward to expanding both our team and services in 2022."

Cymulate released the next generation Extended Security Posture Management (XPSM) platform leveraging its native, offensive security technology and capabilities to widely support customers' security and business needs. XSPM incorporates four fundamental pillars tied together with analytics to provide meaningful security posture insights: Attack Surface Management, Continuous Automated Red Teaming and Breach and Attack Simulation alongside an Advanced Purple Teaming framework.

The company's shift to XPSM followed several product launches including a customizable, template-driven platform that enables security service providers to craft, automate and deliver purple teaming exercises to help their enterprise customers actively protect their networks. Cymulate also released its Attack-Based Vulnerability Management to reduce risk exposure time via an assessment of all unpatched vulnerabilities and empowers security teams to efficiently prioritize patching their networks, resulting in shorter time to remediation and substantial savings. Cymulate Attack Surface Management provides visibility and protection of digital assets located outside the enterprise information network perimeter. The solution was also integrated with Microsoft Defender for Endpoint, EDR and TVM. Cymulate continues to further its platform development with the launch of a collaborative forum, enabling customers, partners and employees access to share working methods and best practices and access Cymulate's latest products. For more information on the Hat Trick Community, seehttps://community.cymulate.com/.

Additional 2021 company highlights include:

  • The appointment of Andrew Barnett as Chief Strategy Officer.
  • The appointment of Wendy Hoey as Vice President of Alliances for the Americas, to lead the company in forming new strategic partnerships and to grow the company's channel alliances.
  • Won several awards including:
  • Frost and Sullivan - Won Best Practices for Global Breach and Attack Simulation Product Leadership Award
  • Cyber Defense Global InfoSec Award - Winner (Breach & Attack Simulation)
  • Cybersecurity Excellence Awards - Winner, Gold (Breach and Attack Simulation)
  • American Business Awards: The Stevies - Winner, Silver (Most Innovative Tech Company of the Year)
  • SC Awards - Europe - Winner (Breach & Attack Simulation)
  • American Security Today - ASTORS Awards - Platinum Winner (Breach & Attack Simulation)

About Cymulate

Cymulate SaaS-based Extended Security Posture Management (XSPM) deploys within an hour, enabling security professionals to continuously challenge, validate and optimize their cyber-security posture end-to-end, across the MITRE ATT&CK framework. The platform provides out-of-the-box, expert and threat intelligence led risk assessments that are simple to deploy and use for all maturity levels, and constantly updated. It also provides an open framework to create and automate red and purple teaming by generating penetration scenarios and advanced attack campaigns tailored to their unique environments and security policies. Cymulate allows professionals to manage, know and control their dynamic environment.

For more information, visit www.cymulate.com and register for a free trial.

Logo - https://mma.prnewswire.com/media/1691967/Cymulate_logo.jpg

Contact for Cymulate:
Levona Simha, Marketing Director at Cymulate
levonas@cymulate.com
IL: +(972) 523 536638

Media contact for Cymulate:
Gina Shaffer
gina.shaffer@si14global.com
US: +1(707) 533-1504
IL: +(972) 54-649-3485

© 2022 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.